OncoMed Pharmaceuticals (OMED) Early-Stage Cancer Antibodies Could Raise ... The Wall Street Transcript “[OncoMed] was a recent IPO this year, and this company is also an antibody-development company or a biotherapeutic company, and they are developing cancer antibodies, and they presently have five early-stage cancer antibodies that are wholly owned ... |
